Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Jahangirnagar University, Savar, Dhaka, Bangladesh.
Department of Genetic Engineering and Biotechnology, School of Life Sciences, Shahjalal University of Science and Technology, Sylhet, Bangladesh.
Expert Rev Vaccines. 2022 Dec;21(12):1851-1871. doi: 10.1080/14760584.2021.1874925. Epub 2021 Mar 15.
The group of human coronaviruses (HCoVs) consists of some highly pathogenic viruses that have caused several outbreaks in the past. The newly emerged strain of HCoV, the SARS-CoV-2 is responsible for the recent global pandemic that has already caused the death of hundreds of thousands of people due to the lack of effective therapeutic options.
In this study, immunoinformatics methods were used to design epitope-based polyvalent vaccines which are expected to be effective against four different pathogenic strains of HCoV i.e., HCoV-OC43, HCoV-SARS, HCoV-MERS, and SARS-CoV-2.
The constructed vaccines consist of highly antigenic, non-allergenic, nontoxic, conserved, and non-homologous T-cell and B-cell epitopes from all the four viral strains. Therefore, they should be able to provide strong protection against all these strains. Protein-protein docking was performed to predict the best vaccine construct. Later, the MD simulation and immune simulation of the best vaccine construct also predicted satisfactory results. Finally, in silico cloning was performed to develop a mass production strategy of the vaccine.
If satisfactory results are achieved in further in vivo and in vitro studies, then the vaccines designed in this study might be effective as preventative measures against the selected HCoV strains.
人类冠状病毒（HCoV）群由一些高致病性病毒组成，这些病毒在过去曾引发过几次爆发。新出现的 HCoV 株，即 SARS-CoV-2，是导致最近全球大流行的原因，由于缺乏有效的治疗选择，已经导致数十万人死亡。
在这项研究中，使用免疫信息学方法设计基于表位的多价疫苗，预计该疫苗将对 HCoV 的四种不同致病株即 HCoV-OC43、HCoV-SARS、HCoV-MERS 和 SARS-CoV-2 有效。
构建的疫苗包含来自所有四种病毒株的高度抗原性、非变应原性、无毒、保守和非同源 T 细胞和 B 细胞表位。因此，它们应该能够提供针对所有这些菌株的强大保护。进行了蛋白质-蛋白质对接以预测最佳疫苗构建体。随后，对最佳疫苗构建体进行 MD 模拟和免疫模拟也预测了令人满意的结果。最后，进行了计算机模拟克隆以开发疫苗的大规模生产策略。
如果在进一步的体内和体外研究中取得满意的结果，那么本研究设计的疫苗可能作为针对所选 HCoV 株的预防措施有效。
